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Abstract Familial DNA cascade screening for familial
hypercholesterolemia (FH) has recently been introduced in
Scotland. This study investigated index patients' experi-
ences of DNA testing and mediating cascade screening.
Thirty-eight patients with a clinical diagnosis of definite or
possible FH who had undergone DNA testing in the lipid
clinic took part in semi-structured qualitative interviews.
All patients were positive about DNA screening being
undertaken by familiar and trusted clinicians within the
lipid clinic. Most patients had already cascaded close
relatives for serum cholesterol testing following their
attendance at the lipid clinic. Identified mutation carriers
who had attended the genetics clinic (n=15) for a cascading
appointment described finding this consultation helpful
because it identified other at-risk family members and
provided them with tailored information for their relatives.
Participants who expressed a preference said they favoured
indirect (patient-mediated) methods of cascading as they
considered indirect approaches to be less threatening to
family members than direct clinical contact. We conclude
that DNA screening and indirect familial cascading is
perceived as highly acceptable to index patients with FH.
However, while indirect cascading methods may be more
acceptable to patients, they do not yield the same numbers
as more direct methods. There is, therefore, a need for
further systematic research to investigate patients', family
members' and staff views of the acceptability of direct
versus indirect methods of cascade screening.
Keywords Familial hypercholesterolemia (FH) . Indirect
cascade screening . Qualitative interviews
Introduction
Ten million people worldwide are at increased risk of
cardiovascular disease and premature death because they carry
a genetic mutation predisposing them to familial hypercholes-
terolemia (FH) (WHO 1998). FH is an autosomal dominant
disease, which manifests as an increase in blood levels of low
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density lipoprotein (LDL) cholesterol. The high atherogenic
LDL cholesterol level is associated with an earlier than
average onset of coronary events, and young people who have
FH (<40 years) have a nearly 100 times increased risk of fatal
heart attack (Neil et al. 2000; Marks et al. 2006). Clinical
diagnosis is based upon a combination of physical and clinical
features including: raised levels of LDL cholesterol, a
significant family history of early onset cardiovascular
disease, and the presence of tendon xanthomas (cholesterol
deposits) (the Simon Broome Criteria (DeMott et al. 2008)).
Early detection and treatment with statins can be effective in
reducing morbidity and mortality in those with heterozygous
FH (DeMott et al. 2008; Scientific Steering Committee 1999).
The severity of FH's consequences and its treatability mean
that screening for this is prioritised by the Department of
Health in the UK (Department of Health 2003). However,
increasing the sensitivity and specificity of diagnosis of FH
requires use of DNA testing (Humphries et al. 2006; Minhas
et al. 2009). DNA screening facilitates diagnosis of younger
pre-symptomatic patients and children in particular (Civeira
et al. 2008; Finnie 2010). DNA testing in combination with
familial cascade screening is seen as a very cost-effective
way of reducing premature death from cardiovascular disease
(Marks et al. 2002; Finnie 2010). Familial cascade DNA
screening is now a clinical reality in Spain (Civeira et al.
2008), Norway (Leren 2004), the Netherlands, Scotland and
Wales and has been recommended in England (DeMott et al.
2008; NICE 2008).
The question of whether cascading should be direct (i.e.
involve direct contact from the clinic using either telephone
calls or letters) or indirect (i.e. mediated by patients who
pass on personalised clinic letters/information) raises a
number of ethical dilemmas, for example, “maximising the
utility of cascade screening” versus respecting probands'
and relatives' privacy and preventing bodily harm in
relatives versus causing psychological harm by under-
mining relatives' right to not know information (Newson
and Humphries 2005 p. 402). Newson and Humphries
(2005) argue that while direct approaches to FH cascading
can be defended on ethical grounds, in practice, it would be
advisable to involve the proband in the process if possible.
Direct FH cascading screening has recently been trialled
in the UK (Hadfield et al. 2009); in line with findings from
an earlier review of the Dutch FH programme (Umans-
Eckenhausen et al. 2001), it was found that systematic
family tracing by trained personnel plus direct clinical
contact results in significantly more relatives coming
forward for cholesterol screening (Hadfield et al. 2009).
Direct approaches have also been supported on the grounds
that they may help overcome patients' reticence to disclose/
distribute information (Suthers et al. 2006) and thus
maximise the number of relatives approached and captured
in the cascade. However, research suggests that family
communication about genetic testing usually takes place
without need for this form of intervention, although the
timing of disclosure may be influenced by social, emotional
and contextual factors (Hallowell 2003). Furthermore,
direct familial cascading is reliant upon index patients
revealing family contact details, and this may raise issues
about confidentiality for some individuals who may prefer
to control the cascading of information in their family
(Hallowell et al. 2003; Horstman and Smand 2008). Finally,
indirect contact could be a more cost-effective option as it
saves training and employing specialist staff to trace and
contact relatives.
While questions have been raised about the most
efficient way of implementing familial cascading for FH
(Marteau et al. 2004; Minhas et al. 2009), limited attention
has been paid to index patients' preferences for different
cascading methods. Some research suggests that direct
cascading is perceived as acceptable to members of the
public (Tonstad et al. 1995) and family members (van
Maarle et al. 2001). However, the former study asked about
a hypothetical scenario (Tonstad et al 1995), and the latter
only assessed the views of first- and second-degree relatives
who had been captured by the cascade, rather than those
initiating the process (van Maarle et al. 2001). Recent
research in the Netherlands has looked at the role played by
index patients in distributing generic information packages
about FH in families (van den Nieuwenhoff et al. 2006).
This study found that index patients preferred to distribute
packages during face–face meetings with close (usually first-
degree) relatives, but were ambivalent about distributing them
tomore distant relatives. To date, no research has looked at the
views of index patients who are involved in initiating or
mediating a familial cascade. Hence, it is not known whether
indirect approaches are acceptable to patients and whether
they raise any practical or ethical concerns. This paper looks at
patients' experience of undergoing DNA testing in the lipid
clinic, their subsequent referral to clinical genetics for family
tracing and their views on having to mediate familial cascade
screening. The objective is to guide and inform the
development of future cascade screening programmes
(Pedersen et al. 2010).
Methods
This study was undertaken in the Lothian region of
Scotland where diagnostic DNA screening targeted at
individuals who met the Simon Broome criteria for the
diagnosis of FH has been ongoing since November 2008.
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The cascading screening service in this region is detailed in
Box 1. The South East Scotland Ethics Committee
approved the study (ref: 09/S1102/66) in January 2010.
In-depth interviews were conducted with index patients
who had participated in DNA screening and familial
cascading consultations. This qualitative design enabled
patients to display their own understandings and experi-
ences of DNA screening and familial cascading and to raise
issues they perceived as most important. To contextualise
the study and enable familiarisation with the DNA
screening process, NJ and NH conducted observations of
a series of consultations in two lipid clinics and a clinical
genetics department, and NJ interviewed eight healthcare
providers associated with these clinics (see Box 1).
Sampling and recruitment
Patients who had undergone DNA screening were recruited
between May–December 2010. One hundred and fourteen
patients who had undergone DNA screening and one
patient who declined testing (total n=115) were contacted
by letter and/or face-to-face by lipid clinic staff. Each
patient received an information sheet outlining the study, an
expression of interest form and a stamped addressed
envelope. Patients were asked to return the expression of
interest form directly to the researchers.
Data collection and analysis
Interviews were conducted by NJ at a time and location (e.g.
patient's home/university offices) chosen by participants.
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With one exception, all interviews were carried out face–
face. Interviews were informed by a topic guide, developed
following clinic observations and informal interviews with
staff and modified in the light of emerging findings.
Interviews explored patients': experiences of attending the
lipid clinic and clinical genetics (if appropriate); under-
standings of FH and its treatment; and perceptions and
experiences of genetic testing, obtaining and interpreting
DNA results and communicating results within the family.
Interviews were digitally recorded (with consent) and
transcribed in full.
Data collection and analysis were concurrent, and interviews
were analysed using the method of constant comparison
(Strauss and Corbin 1990). Interview transcripts were
reviewed by team members and systematically compared in
order to identify cross-cutting themes and highlight common
and divergent experiences between and within groups.
Themes that emerged in early interviews were explored
further in subsequent interviews, in line with an inductive
approach. Data collection ceased when no new themes
emerged. A coding frame was developed to capture data
relating to emergent themes and the primary research aims.
Data were managed using NVivo 8 (QSR International, VIC,
Australia), a data-indexing package.
The sample
Forty three of the 115 (37%) patients who were approached
opted into the study, and 38 (33%) were interviewed; the
remaining patients were either excluded as they did not fit
study criteria or were unavailable for interview. The majority
(79%) were over 45 years of age. All had DNA testing, and
61% were identified as carriers of FH mutations. Fifteen
patients (65%) with a positive DNA result had attended
genetic counselling before the interview. (See Table 1.)
Results
Patients' views of DNA screening in the lipid clinic
All patients talked about valuing the care received in the
lipid clinic, describing the staff who worked there as: “very
charming” (FH11), having a good “bedside or desk-side
manner” (FH12) and as “absolutely fantastic” (FH17).
Many patients had been attending the same lipid clinic for
many years and commented upon the importance of
continuity of care for engendering a trusting relationship
with staff: “I actually quite like it because I know I am
getting looked after and I'll do anything to help them as
well because they have been so good to me over the years
trying different thing.” (FH25).
Patients were overwhelmingly positive about DNA
screening, primarily because they saw it as an opportunity
to confirm that the tendency towards high cholesterol in
themselves and their family was inherited. Many noted that
the routinised nature of phlebotomy in the lipid clinic meant
that DNA testing appeared to be fully integrated into
standard clinic procedures and, therefore, was considered
neither onerous nor a significant event (FH12, Box 2). As
FH36 said, “I didn't consider it, if you like, to be a DNA
test or a genetic test in the sense that it just followed
naturally through”. Indeed, a couple of patients suggested
that, had DNA testing required other, or additional,
procedures (e.g. buccal swabs), they might have thought
more before consenting to this procedure (FH07, Box 2).
Table 1 Patient characteristics
n (%)
Age (years) at interview
Mean 52.63
Range 18–67
≤45 years 8 (21)
Gender
Female/Male 21 (55):17 (45)
Education
Compulsory education 14 (37)
Further education 4 (11)
Higher—HNC/HND 4 (11)
Higher—degree/postgraduate 16 (42)
Current/Most recent occupation
Professional and managerial 11 (29)
Skilled non-manual 9 (24)
Semi-skilled non-manual 11 (29)
Skilled manual 2 (5)
Semi-skilled manual 1 (3)
Routine manual 2 (5)
Other/Unclassified 2 (5)
NHS/(Human) health sector (incl. clerical/admin) 7 (18)
NHS/(Human) health sector (excl. clerical/admin) 5 (13)
Mutation status
Mutation identified/No mutation identified 23 (61):15 (39)
Clinical genetics
Attended genetic counselling 15 (39)
Estimated years attending specialist lipid clinics
0–2 11 (29)
3–4 7 (18)
5–9 7 (18)
10+ 13 (34)
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As far as most patients were concerned, DNA testing
was handled “professionally” and well by clinic staff
(FH42, Box 2). However, a small number described the
administration of the testing process as unnecessarily
cautious (FH09, Box 2) given that they already perceived
their high cholesterol to be familial in origin. While some
patients commented that written notification of their results
had taken a while to arrive, no concerns were raised about
receiving DNA results in a letter rather than face–face.
Patients' views of cascade screening
With the exception of one patient who felt he had not learnt
any new information during his genetics consultation, all
those who attended the genetics clinics were overwhelmingly
positive about their consultation. Patients explained that clinic
attendance had provided opportunities to ask questions and
receive answers about the aetiology and transmission of
disease in their family (FH05, Box 2). Many patients also
described the drawing up of a detailed pedigree as an
important event which had emphasised and illuminated their
family's risks in ways they had not previously considered
(FH05, FH24; Box2). Seeing their family history committed
to paper during the genetics consultation helped clarify
where in the family FH may have come from and where it
might go and, therefore, who needed to be informed. As
FH24 said “…I was quite amazed that they were looking at
cousins…” (See Box 2).
Many patients had come to believe or suspect that high
cholesterol ran in their families prior to being approached to
take part in DNA screening and had already discussed their
condition with their relatives. Lipid clinic staff were
described as having played a pivotal role in encouraging
patients to think about their family members' risk, and some
patients' comments indicated that lipid clinic staff had been
“unofficially” initiating a cascade of family members for
cholesterol screening over a number of years: “[Lipid
consultant] was very clear that the family should take this
seriously and have tests from time to time. I've conveyed
that to them” (FH16). However, family history taking in
these lipid clinics is not systematic, and the staff do not
draw up detailed pedigrees of the whole family or
undertake family tracing. Thus, when patients talked about
who they had contacted following their lipid appointments,
the majority reported only informing (emotionally and
geographically) close kin, primarily, first- (children and
siblings) and second-degree (nieces and nephews) relatives.
A few, however, also said they had, or would, ask an
intermediary (e.g. sister (FH36), parent (FH09, FH 34)) to
relay information to more distant relatives.
The cascading process in the genetics clinic not only
employed a more systematic approach to family history
taking, but also provided patients with leaflets and
personalised letters to forward to at-risk family members
on the clinic's behalf (Box 1). With one exception, all those
who had attended their cascade appointment appreciated the
support received in disseminating information throughout
their family. Patients liked being told who needed to receive
information and being given written information to distribute
to particular relatives rather than having to rely on memory
(FH02, Box 2). Indeed, receiving letters/information to pass
on to more distant relatives—those they saw less frequently or
with whom they were not in contact—was perceived as
particularly helpful. Most patients reported distributing the
information throughout their family as instructed (e.g. FH03,
FH35; Box 2) and, in some cases, that the clinic letters had
already prompted family members to get tested (FH34, Box
2).
Most patients were happy to assume responsibility for
disseminating information about cholesterol or genetic
screening in their family: “…it's [communicating informa-
tion] just something you have to do really, you know, it's a
responsibility you have.” (FH13, FH16; Box 2) When
asked whether they would prefer to be involved in indirect
or direct cascading, the majority expressed a preference for
indirect methods: “Well, I would hate just for a letter to land
on their doorstep saying “would you take part in this?”
(FH37). Patients' accounts suggested that involving the
patients themselves (or another family member) made the
process more personalised and, therefore, potentially less
threatening for relatives (FH07, FH05; Box 2).
Discussion
DNA cascade screening is increasingly becoming the
preferred approach for identifying FH in asymptomatic
individuals, within the UK and across Europe (Leren 2004;
Finnie 2010); however, as Marteau et al. (2004) note,
relatively little is known about the impact on participants,
particularly those initiating the familial cascade. The recent
introduction of DNA cascade screening for FH in Scotland,
therefore, has provided an important and timely opportunity
to explore index patients' views of this service. The data
indicate that index patients, like family members reached
by cascading in the Netherlands (van Maarle et al. 2001),
viewed DNA testing and cascade screening positively.
In contrast to recent research, which suggests that lipid
clinic patients rarely communicate about FH with family
members (Weiner and Durrington 2008), this study, like
earlier Dutch (van den Nieuwenhoff et al. 2007; Horstman
and Smand 2008) and Welsh studies (McDowell et al. 2007),
found that, when given appropriate information and support,
patients do feel willing and able to talk about FH with
relatives and will cascade first-(McDowell et al. 2007) and
second (McDowell et al. 2007; van den Nieuwenhoff et al.
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2007)-degree relatives for cholesterol screening or DNA
testing. These differences may be due to the fact that patients
in this study and these earlier studies (McDowell et al. 2007;
van den Nieuwenhoff et al. 2007) obtained a molecular
rather than just a clinical diagnosis of FH (Weiner and
Durrington 2008). Indeed, authors of the Welsh study
propose that having DNA testing may assist risk communi-
cation in some families. Our data suggest this may be due to
patients attending genetic consultations, where systematic
discussion of the family history during the drawing of the
pedigree helps patients establish which members of the
extended family are at risk and thus who would benefit from
receiving screening information. Thus, cascading appoint-
ments with staff trained in family history taking may
facilitate insight into the genetic transmission of FH and
thus result in more communication with emotionally,
geographically and biologically distant relatives. This is an
important issue to consider as other studies suggest that
many of those who have genetic testing for FH (van den
Nieuwenhoff et al. 2006, 2007), or other genetic conditions
(Hallowell 2003; Hallowell et al. 2003), may be unaware of
the implications for the extended family. In addition,
providing individuals with personalised materials to distribute
to more distant (socially or biologically) family members was
appreciated and perceived as aiding family communication.
These observations suggest that, at least from the index
patient's point of view, referral to clinical genetics for familial
cascading is worthwhile. However, it must be noted that the
fact that FH is not seen as a particularly debilitating or
stigmatising genetic disease and is one which is easily treated
(Jenkins et al., under review) may also increase patients'
apparent willingness to disseminate information within their
family.
Gauging index patients' preferences about the method of
familial cascading is important given the continuing debate
about whether clinicians should contact family members
directly to disclose genetic information and inform them
about the opportunity for predictive testing (Offit et al.
2004; Newson and Humphries 2005). Empirical research
suggests that direct contact by a member of the clinical
team maximises the numbers of family members coming
forward for FH screening (Umans-Eckenhausen et al. 2001;
Hadfield et al. 2009); however, it also raises ethical issues.
For example, an earlier Dutch study of FH cascading
reported that 20% of family members approached reported
feeling under pressure to have DNA testing following direct
clinical contact (van Maarle et al. 2001). The ethico-legal
debate about disclosure of genetic information by clinicians
frequently focuses upon breaches of confidentiality and
patients' right to privacy versus family members' right to
know genetic information about themselves and be informed
about testing/treatment option (Newson and Humphries
2005; Leonard and Newson 2010; Skene and Forrest
2010). This study, like that reported by Horstman and
Smand (2008), suggests that index patients may be less
worried about their own and/or relatives' privacy than
ensuring that their relatives are not made unduly anxious
by unsolicited approaches from the clinical team. Thus, like
those who undergo testing for other dominant disorders
(Hallowell et al. 2003; Kohut et al. 2007), they feel they
should bear the initial responsibility for disseminating
information within their family (Horstman and Smand
2008). It must be noted, however, that while index patients
hypothesised that their involvement in cascading may be
appreciated, or preferred, by their relatives, no cascaded
family members were interviewed in this study, although, as
mentioned above, there is evidence to suggest that
approaches from the clinical team are sometimes perceived
as coercive (van Maarle et al. 2001) or as an invasion of
privacy (Horstman and Smand 2008).
Policy and practice implications
This study lends support for the adoption of indirect methods
of cascading for FH, by highlighting the value that patients
placed on having a systematic family history taken and being
given letters for distribution to relatives, to help them
communicate genetic information within their family. How-
ever, it must be noted that the advantages of employing an
indirect approach may be offset by reduced uptake of
screening amongst relatives (Umans-Eckenhausen et al.
2001; Hadfield et al. 2009). A compromise position might,
therefore, be to encourage index patients to contact family
members in the first instance, thereby allowing them to
discharge their familial obligations and then follow this up, if
required, by direct contact from a healthcare worker
(Newson and Humphries 2005). These observations suggest
more systematic research is needed to compare index
patients' and family members' experiences of the different
methods of familial cascading employed in this and other
studies, as well as the (cost-) effectiveness of each approach.
Strengths and limitations
This is the first study to explore in-depth index patients' views
and experiences of mediating a familial cascade for FH.
When interpreting these findings, it must be noted that this
study included a small, highly educated sample, a sizeable
proportion of whom had previously worked in health-related
occupations, who were the first patients in Scotland to be
offered this type of test, and that these factors may have
influenced their willingness to participate, as well as their
understandings and views. Similar participant characteristics
have been observed in other qualitative studies involving FH
patients attending lipid clinics (Weiner 2006). This may be
due to the fact that lipid clinic patients are not necessarily
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representative of the wider FH population, as fewer than 20%
of all FH patients may be receiving care in specialist lipid
clinics, which are predominantly located in urban areas
(Marks et al. 2004). As a retrospective design was used, it
is possible that patients' accounts may have been subject to
recall bias. Moreover, as patients opted in to the study, it is
possible that those who had more extreme views participated.
Indeed, over 60% of the sample had received a positive DNA
test result, whereas the detection rate for known mutations in
Scotland for 2009–2010 was 29.3% (Bell 2010). We can
speculate that those who received an inconclusive result may
not have felt as motivated to take part as it was clear that
testing was not perceived as such a significant event for this
group (Jenkins et al., under review). Finally, it is possible that
the patients in this study may have been positive about
indirect methods of cascading because this is the method they
are familiar with. Indeed, it has been observed that patients
appear to favour the services they receive (Porter and
Macintyre 1984). This may be the case; however, it should
be noted that a couple of patients who received inconclusive
results and had not been involved in the official cascade also
expressed a preference for indirect methods.
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